Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/02/2005CA2546339A1 Antibacterial aminoquinazolidinedione derivatives
06/02/2005CA2546210A1 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
06/02/2005CA2546200A1 Olanzapine containing transdermal drug delivery compositions
06/02/2005CA2546189A1 Inhibitors of the mutant form of kit
06/02/2005CA2546096A1 4-substituted imidazoles
06/02/2005CA2546093A1 5-substituted imidazoles
06/02/2005CA2546028A1 Novel compounds
06/02/2005CA2546026A1 Synthesis of 2-chloro-3,6-dialkyl pyrazines
06/02/2005CA2546019A1 Therapeutic peg solution concentrate
06/02/2005CA2546013A1 Novel prostamides for the treatment of glaucoma and related diseases
06/02/2005CA2546007A1 Beta-lactams for treatment of cns disorders
06/02/2005CA2545944A1 Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
06/02/2005CA2545915A1 Minimization of drug oxidation in drug irradiated excipients formulations
06/02/2005CA2545834A1 Controlled release of topiramate in liquid dosage forms
06/02/2005CA2545825A1 Hydroxylamine substituted imidazo ring compounds
06/02/2005CA2545802A1 Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
06/02/2005CA2545800A1 Surfactant-based gel as an injectable, sustained drug delivery vehicle
06/02/2005CA2545788A1 Plant-derived protein extract compositions and methods
06/02/2005CA2545725A1 Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
06/02/2005CA2545723A1 Use of cathepsin k inhibitors in severe bone loss diseases
06/02/2005CA2545719A1 Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
06/02/2005CA2545717A1 Anti-tumour terpene compounds
06/02/2005CA2545711A1 Urea derivatives as kinase modulators
06/02/2005CA2545710A1 Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
06/02/2005CA2545641A1 Use of organic compounds
06/02/2005CA2545615A1 Methods and reagents for the treatment of inflammatory disorders
06/02/2005CA2545514A1 Combination of a dpp iv inhibitor and an antiobesity or appetite regulating agent
06/02/2005CA2545513A1 Solid pharmaceutical preparation form
06/02/2005CA2545491A1 Dual molecules containing peroxy derivative, the synthesis and therapeutic applications thereof
06/02/2005CA2545484A1 Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
06/02/2005CA2545267A1 Inhibitor imaging agents
06/02/2005CA2545261A1 Piperidine-substituted indoles- or heteroderivatives thereof
06/02/2005CA2545219A1 Efficient introduction of an aerosol into a ventilator circuit
06/02/2005CA2545196A1 Pyrazolopyrimidines
06/02/2005CA2545193A1 Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
06/02/2005CA2545082A1 Strontium-based complexes, pharmaceutical compositions and dietetic products
06/02/2005CA2545054A1 Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
06/02/2005CA2545049A1 Method for proliferating cardiomyocytes
06/02/2005CA2545048A1 Androgen receptor modulators
06/02/2005CA2545043A1 Combination therapy comprising the use of et-743 and doxorubicin for treating cancer
06/02/2005CA2544769A1 Acremonic acid derivatives
06/02/2005CA2544751A1 Macrocyclic lactams and pharmaceutical use thereof
06/02/2005CA2544573A1 Combinations useful for the treatment of neuronal disorders
06/02/2005CA2544320A1 Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
06/02/2005CA2544230A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic
06/02/2005CA2543315A1 Methods for treating pain
06/02/2005CA2543247A1 Benzannelated compounds as ppar activators
06/02/2005CA2543239A1 Heteroaryl derivatives as ppar activators
06/02/2005CA2542351A1 Combinational radiotherapy and chemotherapy compositions and methods
06/02/2005CA2541293A1 Combinations comprising ampa receptor antagonists for the treatment of schizophrenia
06/02/2005CA2540965A1 Process for preparing clopidogrel compositions
06/02/2005CA2540159A1 Extended release venlafaxine formulation
06/02/2005CA2515890A1 Novel insertion sites in pox vectors
06/02/2005CA2487529A1 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
06/01/2005EP1536011A1 Preventives/remedies for neurodegenerative diseases
06/01/2005EP1536010A1 Preventives/remedies for cancer
06/01/2005EP1535926A1 Carbacyclic phosphatidic acid derivative
06/01/2005EP1535925A1 4,4-Diarylbutadiene functionalized methyltrialkylsilanes and cosmetic or photoprotective dermatological compositions containing them
06/01/2005EP1535923A1 Synthesis of acyclic nucleoside derivatives
06/01/2005EP1535921A1 Method of manufacture of 1,3-oxathiolane nucleosides
06/01/2005EP1535920A1 Process for preparation of 1,3-benzodioxole-2-spiro- cycloalkane derivatives
06/01/2005EP1535919A2 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
06/01/2005EP1535916A1 Clathrates of butylphtualide with cyclodextrin or its derivatives,a process for their preparations and the use there of
06/01/2005EP1535913A1 Novel quaternary ammonium compounds
06/01/2005EP1535911A1 Metabolically inert anti-inflammatory and anti-tumor antifolates
06/01/2005EP1535910A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
06/01/2005EP1535909A2 Cyclic amine derivatives and their use as drugs
06/01/2005EP1535907A1 Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
06/01/2005EP1535906A1 Nitrogen-containing compounds
06/01/2005EP1535902A1 Aminoindan derivatives
06/01/2005EP1535891A1 Remedy
06/01/2005EP1535630A1 Preventive for the onset of diabetes
06/01/2005EP1535629A1 Drugs for improving the prognosis of brain injury and a method of screening the same
06/01/2005EP1535626A2 Actinomyces pyogenes and actinomyces pyogenes/fusobacterium necrophorum vaccines for immunizing cattle and sheep
06/01/2005EP1535623A1 Renal cell carcinoma treatment
06/01/2005EP1535620A1 The use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention
06/01/2005EP1535619A1 Poria extract devoid of secolanostane derivatives comprising lanostane derivatives for immunity enhancement
06/01/2005EP1535618A1 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
06/01/2005EP1535617A1 Remedy or preventive for keratoconjunctival epithelial cell injury
06/01/2005EP1535616A1 Remedy for integration dysfunction syndrome
06/01/2005EP1535615A1 Composition for nasal absorption
06/01/2005EP1535614A2 Materials and methods for detection and treatment of immune system dysfunctions
06/01/2005EP1535613A2 Polymorphic form of atorvastatin calcium
06/01/2005EP1535612A1 Treatment for hyperuricemia
06/01/2005EP1535611A2 Microdose therapy of vascular conditions by no donors
06/01/2005EP1535610A1 Therapeutic agent for cancer
06/01/2005EP1535609A1 Nf-kb activation inhibitors
06/01/2005EP1535606A1 Combination of creatine and/or creatinine with an effective amount of retinoid, in particular retinol and more particularly retinyl palmitate and compositions containing such combinaision.
06/01/2005EP1535605A1 Cosmetic preparations containing creatine, creatinine and/or the derivatives thereof combined with an organic thickener.
06/01/2005EP1535604A1 Combination of creatine and/or creatinine, phenoxyethanol and eventually glycerine
06/01/2005EP1535603A1 Cosmetic or dermatological preparation containing creatin and/or creatinin and concentrations of electrolytes of at least 50 mmol/l
06/01/2005EP1535067A2 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE
06/01/2005EP1534862A2 Modulators of rabggt and methods of use thereof
06/01/2005EP1534847A1 Retroviral vector and stable packaging cell lines
06/01/2005EP1534839A1 Caged tetracycline (derivatives), their generation, and their use for photoactivated gene expression
06/01/2005EP1534832A2 Compositions and methods for tissue specific or inducible inhibition of gene expression
06/01/2005EP1534827A1 Method for generating monoclonal antibodies
06/01/2005EP1534728A2 Antisense modulation of glucocorticoid receptor expression
06/01/2005EP1534727A2 Crystalline and amorphous forms of beta-l-2 -deoxythymidine
06/01/2005EP1534725A2 Compounds and methods for inhibiting selectin-mediated function
1 ... 4670 4671 4672 4673 4674 4675 4676 4677 4678 4679 4680 4681 4682 4683 4684 4685 4686 4687 4688 4689 4690 ... 7860